What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion

R. Vellucci, G. Fanelli, R. Pannuti, C. Peruselli, S. Adamo, G. Alongi, F. Amato, L. Consoletti, L. Lamarca, S. Liguori, C. Lo Presti, A. Maione, S. Mameli, F. Marinangeli, S. Marulli, V. Minotti, D. Miotti, L. Montanari, G. Moruzzi, S. PalermoM. Parolini, P. Poli, W. Tirelli, A. Valle, P. Romualdi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Clinical management of breakthrough cancer pain (BTcP) is still not satisfactory despite the availability of effective pharmacological agents. This is in part linked to the lack of clarity regarding certain essential aspects of BTcP, including terminology, definition, epidemiology and assessment. Other barriers to effective management include a widespread prejudice among doctors and patients concerning the use of opioids, and inadequate assessment of pain severity, resulting in the prescription of ineffective drugs or doses. This review presents an overview of the appropriate and inappropriate actions to take in the diagnosis and treatment of BTcP, as determined by a panel of experts in the field. The ultimate aim is to provide a practical contribution to the unresolved issues in the management of BTcP. Five 'things to do' and five 'things not to do' in the diagnosis and treatment of BTcP are proposed, and evidence supporting said recommendations are described. It is the duty of all healthcare workers involved in managing cancer patients to be mindful of the possibility of BTcP occurrence and not to underestimate its severity. It is vital that all the necessary steps are carried out to establish an accurate and timely diagnosis, principally by establishing effective communication with the patient, the main information source. It is crucial that BTcP is treated with an effective pharmacological regimen and drug(s), dose and administration route prescribed are designed to suit the particular type of pain and importantly the individual needs of the patient.

Original languageEnglish
Pages (from-to)315-330
Number of pages16
JournalDrugs
Volume76
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Breakthrough Pain
Expert Testimony
Pharmacology
Prescription Drugs
Pain Measurement
Cancer Pain
Terminology
Opioid Analgesics
Epidemiology
Communication
Delivery of Health Care
Pain
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Vellucci, R., Fanelli, G., Pannuti, R., Peruselli, C., Adamo, S., Alongi, G., ... Romualdi, P. (2016). What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. Drugs, 76(3), 315-330. https://doi.org/10.1007/s40265-015-0519-2

What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP) : Expert Opinion. / Vellucci, R.; Fanelli, G.; Pannuti, R.; Peruselli, C.; Adamo, S.; Alongi, G.; Amato, F.; Consoletti, L.; Lamarca, L.; Liguori, S.; Lo Presti, C.; Maione, A.; Mameli, S.; Marinangeli, F.; Marulli, S.; Minotti, V.; Miotti, D.; Montanari, L.; Moruzzi, G.; Palermo, S.; Parolini, M.; Poli, P.; Tirelli, W.; Valle, A.; Romualdi, P.

In: Drugs, Vol. 76, No. 3, 01.03.2016, p. 315-330.

Research output: Contribution to journalArticle

Vellucci, R, Fanelli, G, Pannuti, R, Peruselli, C, Adamo, S, Alongi, G, Amato, F, Consoletti, L, Lamarca, L, Liguori, S, Lo Presti, C, Maione, A, Mameli, S, Marinangeli, F, Marulli, S, Minotti, V, Miotti, D, Montanari, L, Moruzzi, G, Palermo, S, Parolini, M, Poli, P, Tirelli, W, Valle, A & Romualdi, P 2016, 'What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion', Drugs, vol. 76, no. 3, pp. 315-330. https://doi.org/10.1007/s40265-015-0519-2
Vellucci, R. ; Fanelli, G. ; Pannuti, R. ; Peruselli, C. ; Adamo, S. ; Alongi, G. ; Amato, F. ; Consoletti, L. ; Lamarca, L. ; Liguori, S. ; Lo Presti, C. ; Maione, A. ; Mameli, S. ; Marinangeli, F. ; Marulli, S. ; Minotti, V. ; Miotti, D. ; Montanari, L. ; Moruzzi, G. ; Palermo, S. ; Parolini, M. ; Poli, P. ; Tirelli, W. ; Valle, A. ; Romualdi, P. / What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP) : Expert Opinion. In: Drugs. 2016 ; Vol. 76, No. 3. pp. 315-330.
@article{59a61141d7a247a5b6f39d68900e8911,
title = "What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion",
abstract = "Clinical management of breakthrough cancer pain (BTcP) is still not satisfactory despite the availability of effective pharmacological agents. This is in part linked to the lack of clarity regarding certain essential aspects of BTcP, including terminology, definition, epidemiology and assessment. Other barriers to effective management include a widespread prejudice among doctors and patients concerning the use of opioids, and inadequate assessment of pain severity, resulting in the prescription of ineffective drugs or doses. This review presents an overview of the appropriate and inappropriate actions to take in the diagnosis and treatment of BTcP, as determined by a panel of experts in the field. The ultimate aim is to provide a practical contribution to the unresolved issues in the management of BTcP. Five 'things to do' and five 'things not to do' in the diagnosis and treatment of BTcP are proposed, and evidence supporting said recommendations are described. It is the duty of all healthcare workers involved in managing cancer patients to be mindful of the possibility of BTcP occurrence and not to underestimate its severity. It is vital that all the necessary steps are carried out to establish an accurate and timely diagnosis, principally by establishing effective communication with the patient, the main information source. It is crucial that BTcP is treated with an effective pharmacological regimen and drug(s), dose and administration route prescribed are designed to suit the particular type of pain and importantly the individual needs of the patient.",
author = "R. Vellucci and G. Fanelli and R. Pannuti and C. Peruselli and S. Adamo and G. Alongi and F. Amato and L. Consoletti and L. Lamarca and S. Liguori and {Lo Presti}, C. and A. Maione and S. Mameli and F. Marinangeli and S. Marulli and V. Minotti and D. Miotti and L. Montanari and G. Moruzzi and S. Palermo and M. Parolini and P. Poli and W. Tirelli and A. Valle and P. Romualdi",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s40265-015-0519-2",
language = "English",
volume = "76",
pages = "315--330",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP)

T2 - Expert Opinion

AU - Vellucci, R.

AU - Fanelli, G.

AU - Pannuti, R.

AU - Peruselli, C.

AU - Adamo, S.

AU - Alongi, G.

AU - Amato, F.

AU - Consoletti, L.

AU - Lamarca, L.

AU - Liguori, S.

AU - Lo Presti, C.

AU - Maione, A.

AU - Mameli, S.

AU - Marinangeli, F.

AU - Marulli, S.

AU - Minotti, V.

AU - Miotti, D.

AU - Montanari, L.

AU - Moruzzi, G.

AU - Palermo, S.

AU - Parolini, M.

AU - Poli, P.

AU - Tirelli, W.

AU - Valle, A.

AU - Romualdi, P.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Clinical management of breakthrough cancer pain (BTcP) is still not satisfactory despite the availability of effective pharmacological agents. This is in part linked to the lack of clarity regarding certain essential aspects of BTcP, including terminology, definition, epidemiology and assessment. Other barriers to effective management include a widespread prejudice among doctors and patients concerning the use of opioids, and inadequate assessment of pain severity, resulting in the prescription of ineffective drugs or doses. This review presents an overview of the appropriate and inappropriate actions to take in the diagnosis and treatment of BTcP, as determined by a panel of experts in the field. The ultimate aim is to provide a practical contribution to the unresolved issues in the management of BTcP. Five 'things to do' and five 'things not to do' in the diagnosis and treatment of BTcP are proposed, and evidence supporting said recommendations are described. It is the duty of all healthcare workers involved in managing cancer patients to be mindful of the possibility of BTcP occurrence and not to underestimate its severity. It is vital that all the necessary steps are carried out to establish an accurate and timely diagnosis, principally by establishing effective communication with the patient, the main information source. It is crucial that BTcP is treated with an effective pharmacological regimen and drug(s), dose and administration route prescribed are designed to suit the particular type of pain and importantly the individual needs of the patient.

AB - Clinical management of breakthrough cancer pain (BTcP) is still not satisfactory despite the availability of effective pharmacological agents. This is in part linked to the lack of clarity regarding certain essential aspects of BTcP, including terminology, definition, epidemiology and assessment. Other barriers to effective management include a widespread prejudice among doctors and patients concerning the use of opioids, and inadequate assessment of pain severity, resulting in the prescription of ineffective drugs or doses. This review presents an overview of the appropriate and inappropriate actions to take in the diagnosis and treatment of BTcP, as determined by a panel of experts in the field. The ultimate aim is to provide a practical contribution to the unresolved issues in the management of BTcP. Five 'things to do' and five 'things not to do' in the diagnosis and treatment of BTcP are proposed, and evidence supporting said recommendations are described. It is the duty of all healthcare workers involved in managing cancer patients to be mindful of the possibility of BTcP occurrence and not to underestimate its severity. It is vital that all the necessary steps are carried out to establish an accurate and timely diagnosis, principally by establishing effective communication with the patient, the main information source. It is crucial that BTcP is treated with an effective pharmacological regimen and drug(s), dose and administration route prescribed are designed to suit the particular type of pain and importantly the individual needs of the patient.

UR - http://www.scopus.com/inward/record.url?scp=84958770940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958770940&partnerID=8YFLogxK

U2 - 10.1007/s40265-015-0519-2

DO - 10.1007/s40265-015-0519-2

M3 - Article

AN - SCOPUS:84958770940

VL - 76

SP - 315

EP - 330

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 3

ER -